TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25475771

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-PRF treatment (control)
Number of subjects: 20
Study: 23427007

Group type: EXPERIMENTAL
Intervention: Low-fat meal with 50,000 IU vitamin D3
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: High-fat meal with 50,000 IU vitamin D3
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: No meal with 50,000 IU vitamin D3
Number of subjects: 62

Group type: COMPARATOR
Intervention: All groups (Low-fat, High-fat, No meal)
Number of subjects: 62
Study: 21287288

Group type: EXPERIMENTAL
Intervention: Cocoa butter (high in stearic acid)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 10
Study: 20031715

Group type: EXPERIMENTAL
Intervention: Nobori Biolimus A9-eluting stent
Number of subjects: 243

Group type: COMPARATOR
Intervention: Taxus Liberté paclitaxel-eluting stent
Number of subjects: 243
Study: 18032083

Group type: EXPERIMENTAL
Intervention: Insulin glargine administered in the morning
Number of subjects: 7

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII) with insulin lispro
Number of subjects: 7
Study: 15309229

Group type: EXPERIMENTAL
Intervention: Early phototherapy (started 12 hours after birth, treated for at least 96 hours)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Late phototherapy (started when transcutaneous bilirubin reached 8 mg/dl, suspended when bilirubin fell to 5 mg/dl)
Number of subjects: 81
Study: 11557835

Group type: EXPERIMENTAL
Intervention: Bupropion (100 mg/d with gradual increase to 200 mg twice daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bupropion (continuation phase)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9631781

Group type: EXPERIMENTAL
Intervention: Early extubation (EE) with reduced dose of fentanyl (15 microg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional extubation (CE) with fentanyl (50 microg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early extubation (EE)
Number of subjects: 100
Study: 8187295

Group type: EXPERIMENTAL
Intervention: Levothyroxine 0.1 mg daily (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment (Group B)
Number of subjects: 100
Study: 2886820

Group type: EXPERIMENTAL
Intervention: Intravenous dihydroergotamine (DHE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 12
Study: 28946534

Group type: EXPERIMENTAL
Intervention: Balance and postural stability exercises in addition to conventional transcutaneous electrical nerve stimulation (TENS), spa and land-based exercises 5 days per week for 3 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional transcutaneous electrical nerve stimulation (TENS), spa and land-based exercises 5 days per week for 3 weeks
Number of subjects: 21
Study: 26632101

Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil (AZL-M) 20, 40, and 80 mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CLD) 12.5 and 25 mg QD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26695605

Group type: EXPERIMENTAL
Intervention: Modified Blumenthal technique of MSICS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 50
Study: 23329787

Group type: EXPERIMENTAL
Intervention: Enteral L-arginine supplementation (1.5 mmol/kg/d bid)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 21119151

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for personality disorders (CBT-PD)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 106
Study: 19066155

Group type: EXPERIMENTAL
Intervention: Ti6A17Nb-alloy (girotan L)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CoCr-alloy (remanium GM 800+)
Number of subjects: 10
Study: 16647419

Group type: EXPERIMENTAL
Intervention: recombinant human arylsulfatase B (rhASB)
Number of subjects: 39

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study: 14604568

Group type: EXPERIMENTAL
Intervention: Combination B vaccine (MSP1, MSP2, RESA) with Montanide ISA 720, 15 microg of each protein given at first and second injection (4 weeks apart)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination B vaccine (MSP1, MSP2, RESA) with Montanide ISA 720, No sulphadoxine-pyrimethamine (SP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (adjuvant emulsified with saline) with No sulphadoxine-pyrimethamine (SP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (adjuvant emulsified with saline) with SP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SP+vaccine
Number of subjects: 120
Study: 10824625

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (steady-state concentrations)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 16
Study: 8880558

Group type: COMPARATOR
Intervention: Blood pressure measured by automatic sphygmomanometer
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clinical BP measurements by male observers
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clinical BP measurements by female observers
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Repeated BP measurements
Number of subjects: 56
Study: 1738925

Group type: EXPERIMENTAL
Intervention: CsA-treated patients
Number of subjects: 411

Group type: COMPARATOR
Intervention: Non-CsA-treated patients
Number of subjects: 411
Study: 6392168

Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 65

Group type: COMPARATOR
Intervention: Renografin-76
Number of subjects: 65
Study: 30961557

Group type: EXPERIMENTAL
Intervention: WhatsApp support messages (60 messages over 3 months)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 132
Study: 30265039

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for attending treatment for 6 weeks
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) for attending treatment for 7-12 weeks
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Twelve weeks of attendance CM
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Attendance-based CM
Number of subjects: 360
Study: 27184989

Group type: EXPERIMENTAL
Intervention: Health coaching intervention
Number of subjects: 441
Study: 25187211

Group type: EXPERIMENTAL
Intervention: Minimum of seven sessions of multidimensional, person‐centred care by HIV nurses trained in palliative care over a period of 5 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 120
Study: 22662730

Group type: EXPERIMENTAL
Intervention: Brief, telephone‐based, cognitive‐behavioral self‐management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18685891

Group type: EXPERIMENTAL
Intervention: Shaker Exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Traditional swallowing therapy
Number of subjects: 11
Study: 17443366

Group type: EXPERIMENTAL
Intervention: Multicomponent physical conditioning program targeting axial and extremity flexibility, coordination, and speed of movement.
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group receiving home, environment safety modules.
Number of subjects: 178
Study: 16365239

Group type: EXPERIMENTAL
Intervention: Mini-laparoscopic cholecystectomy (M-LC)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (C-LC)
Number of subjects: 79
Study: 11952542

Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate at a dose of 10 mg kg(‐1) daily up to 600 mg day(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 80
Study: 9861126

Group type: COMPARATOR
Intervention: Granisetron 3 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Droperidol 1.25 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg with Droperidol 1.25 mg
Number of subjects: 150
Study: 7624737

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 6 g daily (6 enterosoluble tablets of 500 mg AA, twice a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (tartaric acid, TA) 2.55 g daily (213 mg TA, twice a day)
Number of subjects: 24
Study: 2151405

Group type: EXPERIMENTAL
Intervention: Triptorelin (3.2 mg monthly for 6 months)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Buserelin (900 micrograms daily for 6 months)
Number of subjects: 21
Study: 360561

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1,000 mg. twice daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cephalexin 500 mg. four times a day
Number of subjects: 28
Study: 31177906

Group type: EXPERIMENTAL
Intervention: Selective ETA receptor antagonist, sitaxentan
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: Long-acting nifedipine
Number of subjects: 27
Study: 28655128

Group type: EXPERIMENTAL
Intervention: Kinesio taping along with conventional treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 54
Study: 26290009

Group type: EXPERIMENTAL
Intervention: Low-fat dairy
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Low-fat yogurt
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Whole-fat yogurt
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Low-fat milk
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 1868
Study: 23063254

Group type: EXPERIMENTAL
Intervention: Experimental nano-hybrid resin composite (Exite/Tetric EvoCeram)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional hybrid resin composite (Exite/Tetric Ceram)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 52
Study: 21795455

Group type: EXPERIMENTAL
Intervention: 0.08 mg/kg metreleptin (n = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.01, 0.1, and 0.3 mg/kg metreleptin in both fed and fasting conditions for 1 and 3 d
Number of subjects: 20
Study: 19332895

Group type: EXPERIMENTAL
Intervention: Poincaré analysis of arterial oxygen saturation (SaO2) signals
Number of subjects: 117
Study: 17453095

Group type: EXPERIMENTAL
Intervention: Combination of one percent phenol and one percent menthol, twice a day for six weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15475212

Group type: EXPERIMENTAL
Intervention: Post-operative tendons
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Contra-lateral healthy tendons of post-operative subjects
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy tendons of control group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Single traumatic rupture subject
Number of subjects: 3
Study: 11212050

Group type: EXPERIMENTAL
Intervention: Epidural morphine with naloxone (0.208 microg x kg(‐1) x hr(‐1))
Number of subjects: 43

Group type: COMPARATOR
Intervention: Epidural morphine without naloxone (control group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Epidural morphine with naloxone
Number of subjects: 43
Study: 9506771

Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg dexamethasone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg dexamethasone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study: 7816418

Group type: COMPARATOR
Intervention: 0.1 mg digitoxin per day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2904582

Group type: EXPERIMENTAL
Intervention: 30 sessions of intensive dynamic back extensor exercises over three months
Number of subjects: 105

Group type: COMPARATOR
Intervention: A similar programme at one‐fifth the exercise intensity
Number of subjects: 105

Group type: COMPARATOR
Intervention: One month of thermotherapy, massage, and mild exercises
Number of subjects: 105
Study: 30982223

Group type: EXPERIMENTAL
Intervention: pravastatin plus CsA
Number of subjects: 20

Group type: COMPARATOR
Intervention: pravastatin plus placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: OATP1B1 c.521T>C genotype
Number of subjects: 20
Study: 29187416

Group type: EXPERIMENTAL
Intervention: Home-based intervention including adherence support for corrective devices, adaptations to the home environment, communication training, and referral to community-based support services.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Method of implementation of the intervention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Study procedures including outcome assessment measures
Number of subjects: 24
Study: 26939325

Group type: EXPERIMENTAL
Intervention: Moxibustion at Gaohuang (BL 43)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 72
Study: 23465178

Group type: EXPERIMENTAL
Intervention: Primary PSA testing and follow-up testing after ERSPC publication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up testing after a PSA level result of >10 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Referral to a urologist after a PSA level result of >4 ng/mL
Number of subjects: 0
Study: 21349239

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg once daily plus pipamperone 5 mg twice daily (PipCit)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Citalopram plus placebo
Number of subjects: 165
Study: 19916992

Group type: EXPERIMENTAL
Intervention: Normal dose of nelfinavir (1250 mg q12h for 3.5 days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: High dose of nelfinavir (1250 mg q12h for 3 days and single dose of 3125 mg on day 4)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nelfinavir for *1*2 subjects
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nelfinavir for *2*2 subjects
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Active moiety (nelfinavir + M8) for *1*2 and *2*2 subjects
Number of subjects: 66
Study: 17299467

Group type: EXPERIMENTAL
Intervention: Test yoghurt containing GOS (12 g/day), prunes (12 g/day) and linseed (6 g/day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Test yoghurt containing GOS, prunes and linseed
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control yoghurt
Number of subjects: 43
Study: 14618095

Group type: EXPERIMENTAL
Intervention: Morning dosing of amlodipine (5 mg initially, titrated to 10 mg if diastolic BP >= 90 mm Hg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Morning dosing of amlodipine
Number of subjects: 62
Study: 11009051

Group type: EXPERIMENTAL
Intervention: Normal-strength grapefruit juice (200 ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Double-strength grapefruit juice (200 ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple-dose double-strength grapefruit juice (three times daily)
Number of subjects: 12
Study: 9106277

Group type: EXPERIMENTAL
Intervention: Right Visual Field (RVF) stimulation with words at orientations of 0 degrees and 15 degrees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Horizontal presentation format
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other orientations (not specified)
Number of subjects: 0
Study: 1395911

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 to 80 mg daily for 3 months)
Number of subjects: 40
Study: 2869713

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg/kg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1.0 mg/kg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Suxamethonium 0.5 mg/kg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.05 mg/kg and 0.08 mg/kg
Number of subjects: 304

Group type: COMPARATOR
Intervention: Vecuronium vs Pancuronium vs Suxamethonium
Number of subjects: 304
Study: 29110109

Group type: EXPERIMENTAL
Intervention: MRI-based Kellgren and Lawrence (K&L) grading
Number of subjects: 50
Study: 26510643

Group type: EXPERIMENTAL
Intervention: VeinViewer
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard methods
Number of subjects: 53
Study: 24067192

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50, 150, or 300 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine (Study 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram (Study 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day (adjunct therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day (adjunct therapy)
Number of subjects: 0
Study: 22219462

Group type: EXPERIMENTAL
Intervention: Sonography after thoracic surgery (SATS)
Number of subjects: 120
Study: 20586860

Group type: EXPERIMENTAL
Intervention: Sofalcone (300 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cimetidine (800 mg/day)
Number of subjects: 64
Study: 17825448

Group type: EXPERIMENTAL
Intervention: Zolpidem (10mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 16046295

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study: 12421996

Group type: EXPERIMENTAL
Intervention: Native high‐molecular‐weight hyaluronan (Artzal)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Cross‐linked hyaluronan (Synvisc)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Hyaluronan (Artzal or Synvisc pooled)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 10589623

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both (Sevoflurane and Isoflurane)
Number of subjects: 30
Study: 8708713

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate 1.8 mg/kg
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate 2.4 mg/kg
Number of subjects: 609

Group type: COMPARATOR
Intervention: Ondansetron 32 mg
Number of subjects: 609
Study: 1935499

Group type: COMPARATOR
Intervention: Potatoes boiled and consumed fresh at 60 degrees C (Experiment A)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Potatoes boiled, frozen, thawed and consumed at 20 degrees C (Experiment B)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Potatoes boiled, frozen, thawed, reheated to 90 degrees C, and consumed at 60 degrees C (Experiment C)
Number of subjects: 13
Study: 6794713

Group type: EXPERIMENTAL
Intervention: Simple procedure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Angular phenolisation
Number of subjects: 100
Study: 30477800

Group type: EXPERIMENTAL
Intervention: Cystatin C (serum biomarker)
Number of subjects: 5380

Group type: EXPERIMENTAL
Intervention: All renal biomarkers (including urine biomarkers)
Number of subjects: 5380
Study: 30065941

Group type: EXPERIMENTAL
Intervention: Functional Magnetic Stimulation (FMS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (electrode stimulation at supraspinatus and deltoid muscles)
Number of subjects: 30
Study: 26191966

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention plus guideline-level care
Number of subjects: 180

Group type: COMPARATOR
Intervention: Caregiver reports (ADCS-ADL)
Number of subjects: 180
Study: 25481190

Group type: EXPERIMENTAL
Intervention: BCG PSN combined with CO(2) laser
Number of subjects: 102

Group type: COMPARATOR
Intervention: CO(2) laser
Number of subjects: 102
Study: 22101861

Group type: EXPERIMENTAL
Intervention: Hospital-based Pain and Palliative Care Service (PPCS)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 152
Study: 20203161

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 mg intravenously
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17095134

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HHS) 2 ml/kg/10 min (7.2% NaCl with 6% hydroxy ethyl starch 200,000/0.5)
Number of subjects: 66

Group type: COMPARATOR
Intervention: HES alone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HHS)
Number of subjects: 66
Study: 16307956

Group type: EXPERIMENTAL
Intervention: Experimental condition with goal object present
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition with no goal object
Number of subjects: 60
Study: 12461393

Group type: EXPERIMENTAL
Intervention: Circumferential fusion with ALIF Brantigan cage plus posterior instrumentation
Number of subjects: 148

Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion with titanium CD‐Horizon
Number of subjects: 148
Study: 10506878

Group type: EXPERIMENTAL
Intervention: Pristinamycin, 1 g b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid, 500 mg x 4/d
Number of subjects: 0
Study: 7546418

Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Change in beta 2M
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Monitoring serum immunologic markers
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group (matched by baseline CD4 cell count and duration of follow-up)
Number of subjects: 279
Study: 1903019

Group type: EXPERIMENTAL
Intervention: Ritanserin 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7028082

Group type: EXPERIMENTAL
Intervention: Adrenaline 0.5% combined with guanethedine 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adrenaline 1%
Number of subjects: 0
Study: 31669859

Group type: EXPERIMENTAL
Intervention: Dorsal foot flap for thumb reconstruction
Number of subjects: 104

Group type: COMPARATOR
Intervention: Abdominal pedicled flap for thumb reconstruction
Number of subjects: 104
Study: 31120502

Group type: EXPERIMENTAL
Intervention: Aerial ultra-low volume (AULV) applications of chlorpyrifos insecticide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no AULV application)
Number of subjects: 16
Study: 28511548

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0